Government-Owned Inventions; Availability for Licensing, 20644-20645 [2019-09618]

Download as PDF khammond on DSKBBV9HB2PROD with NOTICES 20644 Federal Register / Vol. 84, No. 91 / Friday, May 10, 2019 / Notices Agenda: To review and evaluate grant applications. Place: Virginian Suites, 1500 Arlington Boulevard, Arlington, VA 22209. Contact Person: Baljit S. Moonga, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4214, MSC 7806, Bethesda, MD 20892, 301–435– 1777, moongabs@mail.nih.gov. Name of Committee: Infectious Diseases and Microbiology Integrated Review Group; Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section. Date: June 13–14, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: St. Gregory Hotel, 2033 M Street NW, Washington, DC 20036. Contact Person: Guangyong Ji, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3188, MSC 7808, Bethesda, MD 20892, 301–435– 1146, jig@csr.nih.gov. Name of Committee: Oncology 1-Basic Translational Integrated Review Group; Tumor Progression and Metastasis Study Section. Date: June 13–14, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015. Contact Person: Rolf Jakobi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, 301–495– 1718, jakobir@mail.nih.gov. Name of Committee: Infectious Diseases and Microbiology Integrated Review Group; Clinical Research and Field Studies of Infectious Diseases Study Section. Date: June 13–14, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015. Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301–435– 0903, saadisoh@csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroscience and Neurodegeneration Study Section. Date: June 13–14, 2019. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Alessandra C. Rovescalli, Ph.D., Scientific Review Officer, National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Rm. 5205, VerDate Sep<11>2014 17:03 May 09, 2019 Jkt 247001 MSC7846, Bethesda, MD 20892, (301) 435– 1021, rovescaa@mail.nih.gov. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Biophysics of Neural Systems Study Section. Date: June 13, 2019. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: Bahia Resort Hotel, 998 West Mission Bay Drive, San Diego, CA 92109. Contact Person: Geoffrey G Schofield, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040–A, MSC 7850, Bethesda, MD 20892, 301–435– 1235, geoffreys@csr.nih.gov. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group; Neural Oxidative Metabolism and Death Study Section. Date: June 13–14, 2019. Time: 8:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: Canopy by Hilton, 940 Rose Avenue, North Bethesda, MD 20852. Contact Person: Carol Hamelink, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4192, MSC 7850, Bethesda, MD 20892, (301) 213– 9887, hamelinc@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: May 6, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–09621 Filed 5–9–19; 8:45 am] would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Minority Health and Health Disparities Special Emphasis Panel for Review of Conference Grant (R13) applications. Date: June 12, 2019. Time: 1:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Gateway Building, Suite 525, 7201 Wisconsin Avenue MSC 9205, Bethesda, MD 20892 (Telephone Assisted Meeting). Contact Person: Deborah Ismond, Ph.D., Scientific Review Officer, National Institute on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20906, (301) 451–2432, ismonddr@ mail.nih.gov. Name of Committee: National Institute on Minority Health and Health Disparities Special Emphasis Panel for RCMI Conference Grant applications. Date: June 18, 2019. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Gateway Building, Suite 525, 7201 Wisconsin Avenue MSC 9205, Bethesda, MD 20892. Contact Person: Maryline Laude-Sharp, Ph.D., Scientific Review Officer, National Institute on Minority Health and Health Disparities, National Institutes of Health, 6707 Democracy Blvd., Suite 800, Bethesda, MD 20906, (301) 451–2432, ismonddr@ mail.nih.gov. Dated: May 6, 2019. Ronald J. Livingston, Jr., Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–09616 Filed 5–9–19; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Institute on Minority Health and Health Disparities; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240–627–3705 or SUMMARY: E:\FR\FM\10MYN1.SGM 10MYN1 Federal Register / Vol. 84, No. 91 / Friday, May 10, 2019 / Notices khammond on DSKBBV9HB2PROD with NOTICES Chris.Kornak@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows: Continuous Cell Lines Persistently Expressing High Levels of Native HIV– 1 Envelope Trimers on Their Surface Membrane Description of Technology: Transduced human cell lines expressing high levels of native HIV–1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV–1 envelope for multiple uses, including the highefficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • High-efficiency production of viruslike particles (VLPs). • A means to test new inhibitors or neutralizing antibodies targeting HIV–1 envelope trimers. • Probe for identifying/capturing B cells that produce broadly neutralizing antibodies. Competitive Advantages: • The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form. Development Stage: • Research Use. Inventors: Paolo Lusso (NIAID), Peng Zhang (NIAID). Publications: Zhang, Peng, et al. ‘‘Interdomain stabilization impairs CD4 binding and improves immunogenicity of the HIV–1 envelope trimer.’’ Cell host & microbe 23.6 (2018): 832–844. Licensing Contact: To license this technology please reference E–185– 2018–0, and contact Chris Kornak at 240–627–3705 or Chris.Kornak@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements VerDate Sep<11>2014 17:03 May 09, 2019 Jkt 247001 of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240–627–3705 or Chris.Kornak@nih.gov. Dated: April 30, 2019. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2019–09618 Filed 5–9–19; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2019–0264] Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0105 Coast Guard, DHS. Sixty-day notice requesting comments. AGENCY: ACTION: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting an extension of its approval for the following collection of information: 1625–0105, Regulated Navigation Area; Reporting Requirements for Barges Loaded with Certain Dangerous Cargoes, Inland Rivers, Eighth Coast Guard District and the Illinois Waterway, Ninth Coast Guard District; without change. Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below. DATES: Comments must reach the Coast Guard on or before July 9, 2019. ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG–2019–0264] to the Coast Guard using the Federal eRulemaking Portal at https://www.regulations.gov. See the ‘‘Public participation and request for comments’’ portion of the SUPPLEMENTARY INFORMATION section for further instructions on submitting comments. A copy of the ICR is available through the docket on the internet at https:// www.regulations.gov. Additionally, copies are available from: COMMANDANT (CG–612), ATTN: PAPERWORK REDUCTION ACT SUMMARY: PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 20645 MANAGER, U.S. COAST GUARD, 2703 MARTIN LUTHER KING JR. AVE. SE, STOP 7710, WASHINGTON, DC 20593– 7710. FOR FURTHER INFORMATION CONTACT: Contact Mr. Anthony Smith, Office of Information Management, telephone 202–475–3532, or fax 202–372–8405, for questions on these documents. SUPPLEMENTARY INFORMATION: Public Participation and Request for Comments This notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection’s purpose, the Collection’s likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection. The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection; (2) the accuracy of the estimated burden of the Collection; (3) ways to enhance the quality, utility, and clarity of information subject to the Collection; and (4) ways to minimize the burden of the Collection on respondents, including the use of automated collection techniques or other forms of information technology. Consistent with the requirements of Executive Order 13771, Reducing Regulation and Controlling Regulatory Costs, and Executive Order 13777, Enforcing the Regulatory Reform Agenda, the Coast Guard is also requesting comments on the extent to which this request for information could be modified to reduce the burden on respondents. In response to your comments, we may revise this ICR or decide not to seek an extension of approval for the Collection. We will consider all comments and material received during the comment period. We encourage you to respond to this request by submitting comments and related materials. Comments must contain the OMB Control Number of the ICR and the docket number of this request, [USCG–2019–0264], and must be received by July 9, 2019. Submitting Comments We encourage you to submit comments through the Federal E:\FR\FM\10MYN1.SGM 10MYN1

Agencies

[Federal Register Volume 84, Number 91 (Friday, May 10, 2019)]
[Notices]
[Pages 20644-20645]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-09618]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or

[[Page 20645]]

[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the Technology Transfer and Intellectual Property Office, National 
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, 
Rockville, MD 20852; tel. 301-496-2644. A signed Confidential 
Disclosure Agreement will be required to receive copies of unpublished 
information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Continuous Cell Lines Persistently Expressing High Levels of Native 
HIV-1 Envelope Trimers on Their Surface Membrane

    Description of Technology: Transduced human cell lines expressing 
high levels of native HIV-1 Envelope on their surface membrane, in the 
unmodified or interdomain stabilized form. These cell lines provide a 
stable source of native HIV-1 envelope for multiple uses, including the 
high-efficiency production of virus-like particles (VLPs) for use as 
vaccines, testing new inhibitors or neutralizing antibodies, or 
identifying/capturing B cells that produce broadly neutralizing 
antibodies from infected/vaccinated humans or animals.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     High-efficiency production of virus-like particles (VLPs).
     A means to test new inhibitors or neutralizing antibodies 
targeting HIV-1 envelope trimers.
     Probe for identifying/capturing B cells that produce 
broadly neutralizing antibodies.
    Competitive Advantages:
     The interdomain-stabilized form does not bind CD4 and is 
locked in the native prefusion form.
    Development Stage:
     Research Use.
    Inventors: Paolo Lusso (NIAID), Peng Zhang (NIAID).
    Publications: Zhang, Peng, et al. ``Interdomain stabilization 
impairs CD4 binding and improves immunogenicity of the HIV-1 envelope 
trimer.'' Cell host & microbe 23.6 (2018): 832-844.
    Licensing Contact: To license this technology please reference E-
185-2018-0, and contact Chris Kornak at 240-627-3705 or 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Chris Kornak at 240-627-3705 or 
[email protected].

    Dated: April 30, 2019.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2019-09618 Filed 5-9-19; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.